JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice

Journal of Cellular and Molecular Medicine

Franck Debeurme¹  Catherine Lacout¹  Claudine Moratal²  Rebecca G. Bagley³  William Vainchenker¹  Francisco Adrian³ 

[1] Inserm, U.1009, Institut Gustave Roussy (IGR), Université Paris XI, Villejuif, France;iBV, CNRS UMR7277, INSERM U1091, Université Nice-Sophia Antipolis, Nice, France;Sanofi Oncology, Cambridge, MA, USA

关键词: JAK2 inhibitor;    myeloproliferative neoplasms;    fibrosis;    preclinical murine models;   

DOI  :  10.1111/jcmm.12608

来源: Wiley

【 摘 要 】

Abstract

JAK2 inhibition therapy is used to treat patients suffering from myeloproliferative neoplasms (MPN). Conflicting data on this therapy are reported possibly linked to the types of inhibitors or disease type. Therefore, we decided to compare in mice the effect of a JAK2 inhibitor, Fedratinib, in MPN models of increasing severity: polycythemia vera (PV), post-PV myelofibrosis (PPMF) and rapid post-essential thrombocythemia MF (PTMF). The models were generated through JAK2 activation by the JAK2^V617F mutation or MPL constant stimulation. JAK2 inhibition induced a correction of splenomegaly, leucocytosis and microcytosis in all three MPN models. However, the effects on fibrosis, osteosclerosis, granulocytosis, erythropoiesis or platelet counts varied according to the disease severity stage. Strikingly, complete blockade of fibrosis and osteosclerosis was observed in the PPMF model, linked to correction of MK hyper/dysplasia, but not in the PTMF model, suggesting that MF development may also become JAK2-independent. Interestingly, we originally found a decreased in the JAK2^V617F allele burden in progenitor cells from the spleen but not in other cell types. Overall, this study shows that JAK2 inhibition has different effects according to disease phenotypes and can (i) normalize platelet counts, (ii) prevent the development of marrow fibrosis/osteosclerosis at an early stage and (iii) reduce splenomegaly through blockage of stem cell mobilization in the spleen.

【 授权许可】

CC BY   
© 2015 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.